Truist Financial
SONN

Truist Financial’s Sonnet BioTherapeutics SONN Stock Holding History

Truist Financial’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1
Closed -$15K – 2570
2020
Q1 		$15K Hold
1
– – ﹤0.01% 2343
2019
Q4 		$22K Buy
+1
New +$45.3K ﹤0.01% 2461

Other funds holding SONN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RFA
Reilly Financial Advisors La Mesa, California $1.35B AUM 22.65% 1-Year Est. Return

Truist Financial's SONN Position: Q2 2020 in Review

Truist Financial sold out of Sonnet BioTherapeutics (SONN) in Q2 2020, closing a stake of 1 share — an estimated $15K sold.

Truist Financial first reported a position in SONN in Q4 2019 and held it in 2 quarters. The position peaked at $22K in Q4 2019. 4 funds tracked by Wall St. Rank hold SONN as of Q2 2020.

  • Truist Financial reported no remaining Sonnet BioTherapeutics position as of Q2 2020 after selling out during the quarter.
  • Truist Financial sold 1 Sonnet BioTherapeutics share in Q2 2020, an estimated $15K.
  • Truist Financial first reported a position in Sonnet BioTherapeutics in Q4 2019 and held it in 2 quarters.
  • Truist Financial's Sonnet BioTherapeutics position peaked at $22K in Q4 2019.
  • 4 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q2 2020.

Based on Truist Financial's 13F filing for Q2 2020, filed 14 Aug 2020.